The Michael J. Fox Foundation continually strives to communicate our scientific progress -- at meetings, as well as through peer-reviewed scientific publications.
October 23, 2012
New York, NY - Takeaways from a workshop hosted by The Michael J. Fox Foundation to assess the state of GBA-targeted research for Parkinson's disease. Overall, there was a general sense of excitement for potential Parkinson's-specific research opportunities and therapeutic avenues that have opened up in the GBA field....Read More
October 10, 2012
In recent years, The Michael J. Fox Foundation for Parkinson's Research (MJFF) has endeavored to accelerate progress in Parkinson's disease (PD) research and therapeutic development by decreasing barriers and increasing access to critical resources including verified DNA plasmids, quality antibodies, robust assays and viral vectors encoding target genes of interest. As these have been generated and distributed, ongoing characterization efforts are revealing the utility of each o...Read More
August 19, 2012
American Chemical Society - Philadelphia
As the world's largest private funder of Parkinson's research, The Michael J. Fox Foundation (MJFF) is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. Identification and validation of targets involved in PD pathogenesis is integral to ultimately developing and optimizing therapeutics. Working with academic and industry partners, MJFF has supported the vali...Read More
August 09, 2012
9th International Symposium on Functional Neuroreceptor Mapping of the Living Brain - Baltimore
The Michael J. Fox Foundation (MJFF) is supporting a consortium with the goal of developing a PET radiotracer to image the distribution of alpha-synuclein in the brain. The accumulation of aggregated alpha-synuclein in the brain is the pathological hallmark of Parkinson's disease and is a frequent target for drugs being developed to treat PD. The ability to visualize alpha-synuclein ...Read More
Diurnal and Intersubject Variability of Cerebrospinal Fluid Biomarkers in Parkinsonís Disease and Healthy Volunteers
June 17, 2012
Movement Disorder Society - Dublin, Ireland
Objective: To determine the diurnal fluctuations of specific biomarkers alpha-synuclein, DJ-1, and several amyloid beta species in the cerebrospinal fluid (CSF) of Parkinson's disease (PD) subjects and healthy volunteers and to determine the within-subject and between-subject variability of these markers.
Background: Several biochemical biomarkers are reported to segregate PD from other disorders and may be useful as diagnostic or pr...Read More